[Anti-cytokines in the treatment of idiopathic intestinal inflammations--theory and practice].
Into treatment of idiopathic inflammations of the gut cytokines or their antagonists entered less than 5 years ago and they extended the range of classical medicamentous treatment with aminosalicylates, corticosteroids and immunosuppressives. The theoretical models of their therapeutic application pertained to the blocking of anti-inflammatory cytokines (IL-1, IL-6, IL-8, TNF alpha), the use of immunomodulating cytokines (IL-2, IL-6, IL-8, IL-9) similarly as the therapeutic administration of cytokines with a predominant growth and regulating activity (CSF, TGFalpha, TGFbeta, ODGF, IL-10, IL-11, IL-12). The range is supplemented by ICAM, VCAM antibody oligonucleotides and PAG antagonists. The stage of animal experiments was so far passed only by rhuIL-10, antiIL-2 and PAF antagonists. The only anticytokine which within the record time of 10 years found clinical indication in Crohn's disease, is antiTNF.
Zboril
V
V
Interní gastroenterologická klinika FN Brno.
D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000502:physiology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000503:physiopathology
D016207:Cytokines